CNBC's Bertha Coombs asks President Trump and his team at the White House's announcement on lower prices for Eli Lilly and ...
As you might expect, the competition to win a share of the expanding GLP-1 market is fierce right now, with giants Novo ...
Medpage Today on MSN
Investigational GLP-1-Based Drug Hits MASH Resolution Mark, Misses Fibrosis Target
WASHINGTON -- Treatment with the investigational GLP-1/glucagon dual receptor agonist pemvidutide led to resolution of ...
P opular weight-loss drugs known as GLP-1s could soon become more affordable for Americans. On Thursday, the Trump ...
The agreements with pharma giants Eli Lilly and Novo Nordisk could bring the price of the GLP-1 injectables from roughly ...
Three new Cochrane reviews find evidence that GLP-1 drugs lead to clinically meaningful weight loss, though industry-funded ...
The White House may have struck a deal with Eli Lilly and Novo Nordisk last week to lower the costs of their weight loss ...
GLP-1 drugs tirzepatide and semaglutide may offer increased protection against heart attack, stroke and death from any cause, according to a November study published in Nature Medicine and presented ...
A new University of California San Diego study offers compelling evidence that glucagon-like peptide-1 (GLP-1) receptor ...
President Trump hailed his deal with pharma companies on GLP-1 drug pricing. The question is how big of a difference the deal ...
Medpage Today on MSN
GLP-1 Use Prior to Pregnancy Tied to Lower Gestational Diabetes Risk
ATLANTA -- Women who had been taking GLP-1 receptor agonist medications prior to becoming pregnant had a lower risk of ...
Brooks Nader has kept it candid when it comes to her use of weight-loss drugs.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback